Drug Profile
FROST 450
Alternative Names: FROST-450Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Frost Biologic
- Class Antineoplastics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 25 Jan 2021 Preclinical development in Solid tumours is ongoing in USA (Frost Biologics pipeline, January 2021)
- 25 Jan 2021 FROST 450 is available for licensing as of 25 Jan 2021. http://www.frostbiologic.com/